Back to top

Image: Bigstock

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Read MoreHide Full Article

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

One stock to keep an eye on is Collegium Pharmaceutical (COLL - Free Report) . COLL is currently sporting a Zacks Rank #1 (Strong Buy) and an A for Value.

Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. COLL has a P/S ratio of 0.97. This compares to its industry's average P/S of 2.79.

Finally, we should also recognize that COLL has a P/CF ratio of 5.67. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. COLL's P/CF compares to its industry's average P/CF of 12.69. COLL's P/CF has been as high as 7.17 and as low as 3.49, with a median of 5.10, all within the past year.

Value investors will likely look at more than just these metrics, but the above data helps show that Collegium Pharmaceutical is likely undervalued currently. And when considering the strength of its earnings outlook, COLL sticks out as one of the market's strongest value stocks.

Published in